Sector News

Roche buys U.S.-based Kapa Biosystems

August 20, 2015
Life sciences
(MarketWatch) – Roche Holding AG (ROG.VX) Wednesday said it has bought a U.S. gene-technology company, the latest acquisition in the area by the Swiss pharmaceutical company.
 
Basel-based Roche said it will buy Kapa Biosystems Inc., based in Wilmington, Mass., for an undisclosed sum. The closely held U.S. company has been working on ways to accelerate research into genomes, the complete set of DNA with within a single cell.
 
Roche is interested in the area because it leads to a better understanding of the genetic roots of diseases by identifying genetic mutations. Genome research can affect the future ability to diagnose, monitor and treat cancer and other conditions.
 
Kapa’s protein-engineering technology allows for the generation and screening of large numbers of enzyme variants, Roche said. Tailored enzymes with improved performance for specific applications can be rapidly selected, speeding up product development time lines, the company added.
 
Last week, Roche said it was buying GeneWEAVE BioSciences, a California-based developer of clinical microbiology with diagnostics solutions, for an initial $190 million.
 

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach